Recent Advances in Treating Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with various subtypes, some of which may benefit from specific therapies. Recent efforts to optimize outcomes for DLBCL patients were discussed at the 2024 Debates in Hematology and Oncology Conference by lymphoma expert James O. Armitage. Primary therapy for DLBCL involves prephase therapy, and the addition of rituximab to CHOP has shown improvement. For patients who fail to respond to primary therapy, options include autologous stem cell transplant, chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies, and a potential regimen that avoids conventional chemotherapy. Additionally, the use of circulating tumor DNA (ctDNA) to assess treatment response is an emerging practice. These developments point to a shift towards more personalized treatments for the different subtypes of DLBCL.